Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance (original) (raw)

Nature volume 494, pages 251–255 (2013)Cite this article

Subjects

This article has been updated

Abstract

Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with ≥50% of tumours expressing the BRAF(V600E) oncoprotein1,2. Moreover, the marked tumour regression and improved survival of late-stage _BRAF_-mutated melanoma patients in response to treatment with vemurafenib demonstrates the essential role of oncogenic BRAF in melanoma maintenance3,4. However, as most patients relapse with lethal drug-resistant disease, understanding and preventing mechanism(s) of resistance is critical to providing improved therapy5. Here we investigate the cause and consequences of vemurafenib resistance using two independently derived primary human melanoma xenograft models in which drug resistance is selected by continuous vemurafenib administration. In one of these models, resistant tumours show continued dependency on BRAF(V600E)→MEK→ERK signalling owing to elevated BRAF(V600E) expression. Most importantly, we demonstrate that vemurafenib-resistant melanomas become drug dependent for their continued proliferation, such that cessation of drug administration leads to regression of established drug-resistant tumours. We further demonstrate that a discontinuous dosing strategy, which exploits the fitness disadvantage displayed by drug-resistant cells in the absence of the drug, forestalls the onset of lethal drug-resistant disease. These data highlight the concept that drug-resistant cells may also display drug dependency, such that altered dosing may prevent the emergence of lethal drug resistance. Such observations may contribute to sustaining the durability of the vemurafenib response with the ultimate goal of curative therapy for the subset of melanoma patients with BRAF mutations.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

Change history

The y axis label in Fig. 3c was corrected.

References

  1. Fecher, L. A., Amaravadi, R. K. & Flaherty, K. T. The MAPK pathway in melanoma. Curr. Opin. Oncol. 20, 183–189 (2008)
    Article CAS Google Scholar
  2. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002)
    Article ADS CAS Google Scholar
  3. Sosman, J. A. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707–714 (2012)
    Article CAS Google Scholar
  4. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in _BRAF_-mutant melanoma. Nature 467, 596–599 (2010)
    Article ADS CAS Google Scholar
  5. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010)
    Article CAS Google Scholar
  6. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010)
    Article ADS CAS Google Scholar
  7. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085–3096 (2011)
    Article CAS Google Scholar
  8. Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387–390 (2011)
    Article ADS CAS Google Scholar
  9. Shi, H. et al. Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Commun. 3, 724 (2012)
    Article ADS Google Scholar
  10. Bennett, D. C. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21, 27–38 (2008)
    Article CAS Google Scholar
  11. Petti, C. et al. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res. 66, 6503–6511 (2006)
    Article CAS Google Scholar
  12. Zhu, J., Woods, D., McMahon, M. & Bishop, J. M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12, 2997–3007 (1998)
    Article CAS Google Scholar
  13. Woods, D. et al. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17, 5598–5611 (1997)
    Article CAS Google Scholar
  14. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal regulated kinase activation. Cell 80, 179–185 (1995)
    Article CAS Google Scholar
  15. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968–972 (2010)
    Article ADS CAS Google Scholar
  16. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683–695 (2010)
    Article CAS Google Scholar
  17. Tap, W. D. et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12, 637–649 (2010)
    Article CAS Google Scholar
  18. Hoeflich, K. P. et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 66, 999–1006 (2006)
    Article CAS Google Scholar
  19. Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M. & Tuveson, D. A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 5198–5202 (2003)
    CAS PubMed Google Scholar
  20. Neyns, B., Seghers, A. C., Wilgenhof, S. & Lebbe, C. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 22, 466–472 (2012)
    Article Google Scholar
  21. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012)
    Article ADS CAS Google Scholar
  22. Chmielecki, J. et al. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. J. Thorac. Oncol. 7, 434–442 (2012)
    Article CAS Google Scholar

Download references

Acknowledgements

We thank the members of the Novartis Institutes for BioMedical Reseach (NIBR) Pharmacology department for technical support, comments and discussions during the course of this work. We thank C. Voliva, N. Aziz and E. Collisson for discussions. We thank B. Weisburd and the rest of the NIBR Bioinformatics department for assistance with exome sequencing data analysis. We thank S. Kaufman for sharing her knowledge of cell-based assays. We thank V. Marsh, N. Rosen, P. Poulikakos and D. Solit for providing additional advice and reagents. M.D.T. was supported by an NIBR Presidential Postdoctoral Fellowship. M.M. acknowledges support from the Melanoma Research Alliance and the National Cancer Institute (R01-CA176839). A.S.L. was supported by a National Research Service Award T32 training grant HL007185.

Author information

Authors and Affiliations

  1. Novartis Institutes for Biomedical Research, Emeryville, 94608, California, USA
    Meghna Das Thakur, Fernando Salangsang, Nancy K. Pryer & Darrin D. Stuart
  2. Helen Diller Family Comprehensive Cancer Center & Department of Cellular & Molecular Pharmacology, University of California San Francisco, California, 94143-0128, USA
    Allison S. Landman & Martin McMahon
  3. Novartis Institutes for Biomedical Research, Cambridge, 02139, Massachusetts, USA
    William R. Sellers
  4. Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland,
    Mitchell P. Levesque & Reinhard Dummer

Authors

  1. Meghna Das Thakur
    You can also search for this author inPubMed Google Scholar
  2. Fernando Salangsang
    You can also search for this author inPubMed Google Scholar
  3. Allison S. Landman
    You can also search for this author inPubMed Google Scholar
  4. William R. Sellers
    You can also search for this author inPubMed Google Scholar
  5. Nancy K. Pryer
    You can also search for this author inPubMed Google Scholar
  6. Mitchell P. Levesque
    You can also search for this author inPubMed Google Scholar
  7. Reinhard Dummer
    You can also search for this author inPubMed Google Scholar
  8. Martin McMahon
    You can also search for this author inPubMed Google Scholar
  9. Darrin D. Stuart
    You can also search for this author inPubMed Google Scholar

Contributions

M.D.T., M.M. and D.D.S. designed all experiments. M.D.T. performed in vivo and in vitro experiments and collected data. M.D.T., M.M. and D.D.S. analysed data, wrote the paper and guided the manuscript through review. F.S. assisted in performing in vivo experiments. A.S.L. carried out the clonogenic assay with the SK-Mel-239-C3 cells. M.P.L. and R.D. provided the human patient biopsy samples, and R.D. assisted with data analysis and interpretation. W.R.S. and N.K.P. provided input on the experimental approach and on the manuscript. M.M. and D.D.S. are co-senior authors of this manuscript.

Corresponding authors

Correspondence toMartin McMahon or Darrin D. Stuart.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

PowerPoint slides

Rights and permissions

About this article

Cite this article

Das Thakur, M., Salangsang, F., Landman, A. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.Nature 494, 251–255 (2013). https://doi.org/10.1038/nature11814

Download citation

Editorial Summary

A counter to vemurafenib resistance?

Although BRAF inhibitors such as vemurafenib have shown very promising effects in patients with BRAF-mutant melanomas, these tumours generally develop resistance. To understand the causes and consequences of this resistance, Meghna Das Thakur et al. investigate the response of patient-derived melanomas, grafted in mice, to vemurafenib. Paradoxically, they find that in these mouse models, vemurafenib-resistant melanomas become drug dependent, such that drug discontinuation leads to tumour regression. On the basis of these results, they demonstrate that an intermittent dosing schedule can prevent the development of drug resistance. Although the clinical relevance of these findings remains to be determined, this work suggests that vemurafenib efficacy might be improved by intermittent dosing.